• Print
  • Share
close

Share this on...

Share this site with others using one of these sharing tools.

 

Link to this article

To link to this article, paste this block of HTML code onto your webpage.

Guidelines for sites linking to mayoclinic.org

Focal Segmental Glomerulosclerosis

Clinical Trials

Below is a list of Focal Segmental Glomerulosclerosis clinical trials from the clinical trials database at Mayo Clinic.

Mayo's clinical trials include experimental treatments, often unavailable elsewhere, which frequently lead to improved patient care for people worldwide. Patients should ask their doctor at Mayo about clinical trials appropriate for their situation.

Novel Therapies for Resistant FSGS (FONT II): Phase II Clinical Trial
SPECIFIC AIMS A significant percentage of patients with primary FSGS are resistant to corticosteroids and other immunosuppressive medications. In view of the rising incidence of this disease and the grim prognosis for patients with resistant disease, it is imperative that new therapeutic approaches be evaluated in an efficient and systematic manner.
Read more

Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors
OBJECTIVES: Primary - To compare the overall survival (OS) of subjects receiving the combination of temozolomide and irinotecan with that of subjects receiving temozolomide, irinotecan, and bevacizumab for recurrent medulloblastoma (MB)/PNET of childhood.
Read more

  • Print

Find Mayo Clinic on


Terms of Use and Information Applicable to this Site
Copyright ©2001-2012 Mayo Foundation for Medical Education and Research. All Rights Reserved.

.